by Frank Bergman
In a groundbreaking development for cancer treatment, scientists have announced that ivermectin may offer new hope in the battle against chemotherapy-resistant ovarian cancer.
Ivermectin, most commonly known as an antiparasitic, has been emerging as a major new treatment in fighting multiple forms of cancer.
The study was led by Dr. Cláudia Santos and conducted by researchers from UCIBIO and CESPU.
The findings were published in the medical journal Scientific Letters.
The study reveals that ivermectin may play a key role in overcoming chemotherapy resistance by targeting a critical protein marker, ALDH1.
ALDH1 has been linked to poor treatment responses and tumor relapse.
The research demonstrates that when ivermectin was combined with chemotherapy agents carboplatin and paclitaxel, ovarian cancer cells showed a dramatic decrease in ALDH1 expression.
The scientists note that this is a key factor in chemotherapy resistance.
The results were obtained from both standard and paclitaxel-resistant ovarian cancer cell lines and under different growth conditions, including 2D and 3D cell cultures.
The combination therapy significantly outperformed treatments using chemotherapy alone.
The findings provide a promising avenue to enhance the effectiveness of existing cancer therapies.
full story at https://slaynews.com/news/scientists-make-major-breakthrough-treating-cancer-ivermectin/
The post Scientists Make Major Breakthrough in Treating Cancer with Ivermectin appeared first on Conservative News & Right Wing News | Gun Laws & Rights News Site
.
Click this link for the original source of this article.
Author: Admin
This content is courtesy of, and owned and copyrighted by, https://rightedition.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
